[
    {
        "title": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 24h - Schedule of Dr. Reddy's analyst and institutional investor meetings in June 2025.",
        "link": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e93e6ba0-8624-477e-bad2-f7ca5dfd766c.pdf",
        "date": "24h - Schedule of Dr. Reddy's analyst and institutional investor meetings in June 2025."
    },
    {
        "title": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 1d",
        "link": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9293C8F3_771C_42BE_9264_38CFFD04E189_101609.pdf",
        "date": "1d"
    },
    {
        "title": "Announcement under Regulation 30 (LODR)-Press Release / Media Release 1d - Dr. Reddy's and Alvotech collaborate to co-develop biosimilar to $29.5B Keytruda for global markets.",
        "link": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c65efc1e-568f-4086-b884-31d4875a65f3.pdf",
        "date": "1d - Dr. Reddy's and Alvotech collaborate to co-develop biosimilar to $29.5B Keytruda for global markets."
    },
    {
        "title": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 3 Jun",
        "link": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98c15db4-802a-4aba-8676-772ee25008e0.pdf",
        "date": "3 Jun"
    },
    {
        "title": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 31 May - Tax reassessment notice of Rs.2395.82 Cr for AY 2020-21 post merger with indemnity by promoters.",
        "link": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=872d57c6-0dcb-4f4f-91e0-1eae6385ea07.pdf",
        "date": "31 May - Tax reassessment notice of Rs.2395.82 Cr for AY 2020-21 post merger with indemnity by promoters."
    }
]